Develops bispecific antibodies for immuno-oncology therapies, focusing on targeting tumor cells with enhanced specificity.
LAVA Therapeutics N.V., a pioneering clinical-stage immuno-oncology company, is dedicated to revolutionizing cancer treatment. Leveraging its innovative Gammabody platform, LAVA Therapeutics develops a diverse portfolio of bispecific antibodies. These antibodies are engineered to harness the potent capabilities of gamma delta T cells, aiming to provoke robust anti-tumor immune responses that could significantly improve outcomes for cancer patients. The company's leading candidates include LAVA-051, currently undergoing Phase 1/2a trials targeting blood cancers such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Additionally, LAVA-1207 is advancing through Phase 1/2a trials for metastatic castration-resistant prostate cancer.
Based in Utrecht, the Netherlands, LAVA Therapeutics N.V. operates at the forefront of oncological research and development. Beyond its clinical-stage assets, the company's pipeline includes promising Gammabody candidates like LAVA-1223, designed to target the epidermal growth factor receptor (EGFR) for selected solid tumors, along with preclinical candidates LAVA-1266 and LAVA-1278, intended for hematologic malignancies. A strategic research collaboration and license agreement with Janssen Biotech, Inc. further underscores LAVA Therapeutics' commitment to pioneering multi-specific antibody products tailored for various therapeutic applications.
Founded in 2016, LAVA Therapeutics N.V. continues to expand its scientific expertise and therapeutic footprint in immuno-oncology. With a steadfast focus on innovation and patient-centric care, the company remains poised to redefine standards in cancer therapy, aiming to address critical unmet needs and provide new hope for patients worldwide.